Parkinsonism and the hypotension caused by L-dopa.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D001812:Blood-Brain Barrier; D004295:Dihydroxyphenylalanine / Q000009:adverse effects* / Q000378:metabolism; D004106:Dilatation; D004357:Drug Synergism; D006801:Humans; D007022:Hypotension / Q000139:chemically induced*; D007275:Injections, Intravenous; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D011187:Posture; D011680:Pupil / Q000187:drug effects; D012965:Sodium Chloride / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D008996:Monoamine Oxidase Inhibitors; D012965:Sodium Chloride; D004295:Dihydroxyphenylalanine